Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

N0550000

Neostigmine methyl sulfate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

3-(N,N-Dimethylcarbamoyloxy)-N,N,N,-trimethylanilinium methyl sulfate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C13H22N2O6S
CAS Number:
51-60-5
Molecular Weight:
334.39
MDL number:
MFCD00011796
UNSPSC Code:
41116107
PubChem Substance ID:
329818445
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

neostigmine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

COS([O-])(=O)=O.CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C

InChI

1S/C12H19N2O2.CH4O4S/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5;1-5-6(2,3)4/h6-9H,1-5H3;1H3,(H,2,3,4)/q+1;/p-1

InChI key

OSZNNLWOYWAHSS-UHFFFAOYSA-M

Gene Information

human ... ACHE(43)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Neostigmine methyl sulfate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Reversible inhibitor of acetylcholinesterase that is similar to eserine, but does not cross the blood-brain barrier.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

Signal Word

Danger

Hazard Statements

H300,H315,H319,H334,H335

Hazard Classifications

Acute Tox. 2 Oral - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Michael Benatar et al.
The Cochrane database of systematic reviews, 12, CD005081-CD005081 (2012-12-14)
Approximately 50% of people with myasthenia gravis present with purely ocular symptoms, so called ocular myasthenia. Of these between 50% to 60% develop generalized disease, most within two years. Their management is controversial. This is an update of a review
Martina Grosse-Sundrup et al.
BMJ (Clinical research ed.), 345, e6329-e6329 (2012-10-19)
To determine whether use of intermediate acting neuromuscular blocking agents during general anesthesia increases the incidence of postoperative respiratory complications. Prospective, propensity score matched cohort study. General teaching hospital in Boston, Massachusetts, United States, 2006-10. 18,579 surgical patients who received
Oyun Khookhor et al.
Neuro endocrinology letters, 34(1), 58-61 (2013-03-26)
We previously demonstrated that the direct microinjection of cholinesterase inhibitor (neostigmine) into the hippocampus in rats activated the hypothalamo-pituitary -adrenal axis and increased the level of norepinephrine in the plasma. In the current study we tried to measure the effects
Christian Lyngsaa Lang et al.
Ugeskrift for laeger, 175(16), 1120-1121 (2013-05-09)
The case report describes a 37-year-old woman who was diagnosed with Ogilvie's syndrome after caesarean section. Conservative treatment was initiated with minimal effect, and the patient was subsequently treated with IV neostigmine. A computed tomography of the abdomen revealed enlarged
Jakub Fichna et al.
Pharmacological reports : PR, 64(5), 1146-1154 (2012-12-15)
Animal models of visceral pain have gained much attention as an important tool to elucidate the possible mechanisms underlying functional gastrointestinal (GI) disorders. Here we report the development of a new, minimally invasive behavioral model of abdominal pain induced by
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service